Kymera Therapeutics Investor Relations Material

Kymera Therapeutics, Inc. is a biopharmaceutical company focused on discovering and developing targeted protein degradation therapies. The company’s proprietary platform aims to design small-molecule drugs that selectively degrade disease-causing proteins, offering a novel approach to treating conditions that have been difficult to address with traditional therapies. Kymera Therapeutics is engaged in research and development across various therapeutic areas, including oncology, immunology, and inflammation. The company is headquartered in Watertown, United States, and its shares are listed on the NASDAQ.